Literature DB >> 20094777

Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis.

Yoshiyuki Suzuki1, Kenji Ikeda, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Fumitaka Suzuki, Satoshi Saitoh, Yasuji Arase, Mariko Kobayashi, Yuzo Miyakawa, Hiromitsu Kumada.   

Abstract

BACKGROUND: Influence of human lymphocyte antigen (HLA) on the therapeutic response in autoimmune hepatitis (AIH) is not known. AIMS: To evaluate if HLA-DR types influence biological and histological responses to corticosteroids in patients with AIH.
METHODS: During 28 years from 1979 through 2007, 48 patients with definite diagnosis of AIH received long-term corticosteroid therapy (median 9 years [range: 5-28 years]) in a single Japanese center. They were followed for transaminase levels and received liver biopsy before and after the treatment.
RESULTS: DR4 was detected in 32 and DR14 in 11 patients; seven possessed both DR4 and DR14. DR4 was more frequent in AIH patients than in the general population (67% vs. 22%), while DR14 was comparably frequent between them (23% vs. 17%). Overall, biochemical response was achieved in 43 (90%) of the 48 patients. The sustained biochemical response to a maintenance prednisolone dose < 10 mg was gained more frequently in the patients with than without DR14 (10/11 [91%] vs. 10/37 [27%], P < 0.001). Marked histological improvement with a decrease in histology activity index (HAI) score by > 2 points was achieved in 31 of the 32 (97%) biochemical responders. Histological aggravation with an increase in HAI score occurred in 4 of the 16 (25%) patients without biochemical response (non-responders and relapsers combined), but in none of the 32 responders.
CONCLUSION: Long-term immunosuppressive treatment can improve the outcome of Japanese patients with AIH, and DR14 is associated with excellent biochemical response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20094777     DOI: 10.1007/s10620-009-0995-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

Review 1.  Autoimmune hepatitis: clinical challenges.

Authors:  M P Manns; C P Strassburg
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

Review 2.  Autoimmune hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  Autoimmun Rev       Date:  2003-09       Impact factor: 9.754

3.  Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis.

Authors:  M D Strettell; P T Donaldson; L J Thomson; P J Santrach; S B Moore; A J Czaja; R Williams
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

4.  Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition.

Authors:  M Pando; J Larriba; G C Fernandez; H Fainboim; M Ciocca; M Ramonet; I Badia; J Daruich; J Findor; H Tanno; C Cañero-Velasco; L Fainboim
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

6.  Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis.

Authors:  Kaname Yoshizawa; Masao Ota; Yoshihiko Katsuyama; Tetsuya Ichijo; Akihiro Matsumoto; Eiji Tanaka; Kendo Kiyosawa
Journal:  J Hepatol       Date:  2005-01-21       Impact factor: 25.083

7.  Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors.

Authors:  P T Donaldson; D G Doherty; K M Hayllar; I G McFarlane; P J Johnson; R Williams
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

Review 8.  Treatment challenges and investigational opportunities in autoimmune hepatitis.

Authors:  Albert J Czaja; Francesco B Bianchi; Herschel A Carpenter; Edward L Krawitt; Ansgar W Lohse; Michael P Manns; Ian G McFarlane; Giorgina Mieli-Vergani; Gotaro Toda; Diego Vergani; John Vierling; Mikio Zeniya
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

9.  Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States.

Authors:  Albert J Czaja; Enrico O Souto; Paulo L Bittencourt; Eduardo L R Cancado; Gilda Porta; Anna Clara Goldberg; Peter T Donaldson
Journal:  J Hepatol       Date:  2002-09       Impact factor: 25.083

10.  Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.

Authors:  Albert J Czaja; Herschel A Carpenter
Journal:  J Hepatol       Date:  2004-04       Impact factor: 25.083

View more
  3 in total

1.  Genetic background of autoimmune hepatitis in Japan.

Authors:  Kaname Yoshizawa; Takeji Umemura; Masao Ota
Journal:  J Gastroenterol       Date:  2010-10-19       Impact factor: 7.527

2.  Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis.

Authors:  Yohei Furumoto; Toru Asano; Tomonori Sugita; Hiroshi Abe; Yoshimichi Chuganji; Kazuhiko Fujiki; Akihiko Sakata; Yoshio Aizawa
Journal:  BMC Gastroenterol       Date:  2015-10-21       Impact factor: 3.067

Review 3.  Autoimmune Hepatitis in the Asia-Pacific Area.

Authors:  Qi-Xia Wang; Li Yan; Xiong Ma
Journal:  J Clin Transl Hepatol       Date:  2017-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.